Guoming Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Guoming Hu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Feng Xu
Department of General Surgery (Breast and Thyroid Surgery), Shaoxing People’s Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Zhejiang 312000, China
1 shared publicationJiaming Dong
School of Medicine, Shaoxing University, Shaoxing, China
1 shared publicationJingjing Hu
School of Medicine, Shaoxing University, Shaoxing, China
1 shared publicationKefang Zhong
Department of General Surgery (Breast and Thyroid Surgery), Shaoxing People’s Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Zhejiang 312000, China
1 shared publicationLiming Huang
Department of General Surgery (Breast and Thyroid Surgery), Shaoxing People’s Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Zhejiang 312000, China
1 shared publicationLiwei Meng
Department of General Surgery (Breast and Thyroid Surgery), Shaoxing People’s Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Zhejiang 312000, China
1 shared publication
Latest Publications
- Open Access
- 28 January 2025
- Published by Springer Nature in Research Square
Global burden of brain and other central nervous system cancer in older adults aged over 65: a population-based study
Background Brain and central nervous system cancer remains a major healthy concern among the elder worldwide. This study is performed to assess the global burden of CNS cancer among adults aged ≥ 65 years across 204 countries and territories from 1990 to 2021 and to predict future trends in the next 25 years. Methods We analyzed the incidence, mortality and disability adjusted life years (DALYs) based on data from the Global Burden of Disease Study 2021. In addition, we obtained and analyzed the age-standardized incidence rate (ASIR), age‐standardized death rate (ASDR), and age‐standardized DALYs rate during 1990–2021. Then we assessed the impact of geographical variations and the Socio‐demographic Index (SDI) on disease burden of CNS cancer. Furthermore, we calculated EAPC and AAPC to reveal temporal trends of CNS cancer incidence and mortality among adults aged ≥ 65 years. Results Globally, CNS cancer incident cases among adults aged ≥ 65 years increased from 40344 in 1990 to 130100 in 2021. The ASIR rose from 3.7 to 4.3 per 100,000 (EAPC:0.44, 95% CI: 0.4–0.49). Low-middle SDI regions showed the largest ASIR increase (EAPC:1.04, 95% CI: 0.99–1.09), while High SDI regions had the lowest (EAPC:0.43, 95% CI: 0.36–0.5). The global ASDR rose from 3 per 100,000 in 1990 to 3.1 per 100,000 in 2021, and the age-standardized DALYs rate decreased from 119.9 to 107.9 per 100,000 between 1990 and 2021. Geographically, the incidence and mortality rates of CNS cancer among adults aged ≥ 65 years increased in most countries and territories. Conclusion The global burden of CNS cancer among the elder has risen sharply from 1990 to 2021, with divisions and disparities observed across different regions. Specific medical interventions and policies to consolidate early detection and better healthcare service in impoverished regions are essential for reducing the global impact of CNS cancer.
- 28 January 2025
- Published by Springer Nature in Research Square
Open AccessGlobal burden of brain and other central nervous system cancer in older adults aged over 65: a population-based study
Background Brain and central nervous system cancer remains a major healthy concern among the elder worldwide. This study is performed to assess the global burden of CNS cancer among adults aged ≥ 65 years across 204 countries and territories from 1990 to 2021 and to predict future trends in the next 25 years. Methods We analyzed the incidence, mortality and disability adjusted life years (DALYs) based on data from the Global Burden of Disease Study 2021. In addition, we obtained and analyzed the age-standardized incidence rate (ASIR), age‐standardized death rate (ASDR), and age‐standardized DALYs rate during 1990–2021. Then we assessed the impact of geographical variations and the Socio‐demographic Index (SDI) on disease burden of CNS cancer. Furthermore, we calculated EAPC and AAPC to reveal temporal trends of CNS cancer incidence and mortality among adults aged ≥ 65 years. Results Globally, CNS cancer incident cases among adults aged ≥ 65 years increased from 40344 in 1990 to 130100 in 2021. The ASIR rose from 3.7 to 4.3 per 100,000 (EAPC:0.44, 95% CI: 0.4–0.49). Low-middle SDI regions showed the largest ASIR increase (EAPC:1.04, 95% CI: 0.99–1.09), while High SDI regions had the lowest (EAPC:0.43, 95% CI: 0.36–0.5). The global ASDR rose from 3 per 100,000 in 1990 to 3.1 per 100,000 in 2021, and the age-standardized DALYs rate decreased from 119.9 to 107.9 per 100,000 between 1990 and 2021. Geographically, the incidence and mortality rates of CNS cancer among adults aged ≥ 65 years increased in most countries and territories. Conclusion The global burden of CNS cancer among the elder has risen sharply from 1990 to 2021, with divisions and disparities observed across different regions. Specific medical interventions and policies to consolidate early detection and better healthcare service in impoverished regions are essential for reducing the global impact of CNS cancer.
- Open Access
- 15 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Erythrocyte modified controlling nutritional status as a biomarker for predicting poor prognosis in post-surgery breast cancer patients
Nutrition and inflammation are closely related to prognosis in breast cancer patients. However, current nutritional and inflammatory measures predict disease free survival (DFS) of breast cancer are still different, and the most predictive measures remain unknown. This study aimed to compare the predictive effects of commonly used nutritional and inflammatory measures on DFS and to improve existing nutritional or inflammatory measures in order to develop a new model that is more effective for predicting postoperative recurrence and metastasis in breast cancer patients. The clinical data of 536 female breast cancer patients with invasive ductal carcinoma who underwent surgery at Shaoxing People’s Hospital from January 2012 to December 2018 were retrospectively evaluated. The predictive effects of nutritional and inflammatory indicators on DFS were evaluated. Machine learning was used to evaluate and rank laboratory indicators, select relatively important variables to modify nutritional or inflammatory indicators with the best predictive power, and evaluate their predictive role in patients’ postoperative recurrence and metastasis. Among various metrics predicting DFS, the CONUT score emerged paramount with an area under the curve (AUC) of 0.667. Interestingly, the combination of the erythrocyte levels with the CONUT score (ECONUT) achieved the highest AUC (0.722). The Kaplan-Meier survival analysis showed that the group exhibiting high ECONUT scores experiencing a notably poorer DFS. ECONUT was identified as an independent risk factor for postoperative DFS (P < 0.001). The ECONUT model could provide an effective assessment tool for predicting DFS in breast cancer patients.
- 15 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Open AccessErythrocyte modified controlling nutritional status as a biomarker for predicting poor prognosis in post-surgery breast cancer patients
Nutrition and inflammation are closely related to prognosis in breast cancer patients. However, current nutritional and inflammatory measures predict disease free survival (DFS) of breast cancer are still different, and the most predictive measures remain unknown. This study aimed to compare the predictive effects of commonly used nutritional and inflammatory measures on DFS and to improve existing nutritional or inflammatory measures in order to develop a new model that is more effective for predicting postoperative recurrence and metastasis in breast cancer patients. The clinical data of 536 female breast cancer patients with invasive ductal carcinoma who underwent surgery at Shaoxing People’s Hospital from January 2012 to December 2018 were retrospectively evaluated. The predictive effects of nutritional and inflammatory indicators on DFS were evaluated. Machine learning was used to evaluate and rank laboratory indicators, select relatively important variables to modify nutritional or inflammatory indicators with the best predictive power, and evaluate their predictive role in patients’ postoperative recurrence and metastasis. Among various metrics predicting DFS, the CONUT score emerged paramount with an area under the curve (AUC) of 0.667. Interestingly, the combination of the erythrocyte levels with the CONUT score (ECONUT) achieved the highest AUC (0.722). The Kaplan-Meier survival analysis showed that the group exhibiting high ECONUT scores experiencing a notably poorer DFS. ECONUT was identified as an independent risk factor for postoperative DFS (P < 0.001). The ECONUT model could provide an effective assessment tool for predicting DFS in breast cancer patients.
- Open Access
- 3 May 2021
- Published by Impact Journals, LLC in Aging
- Vol. 13 (10) , 13693-13707
PDGFR-β+ fibroblasts deteriorate survival in human solid tumors: a meta-analysis
Fibroblasts are a highly heterogeneous population in tumor microenvironment. PDGFR-β+ fibroblasts, a subpopulation of activated fibroblasts, have proven to correlate with cancer progression through multiple of mechanisms including inducing angiogenesis and immune evasion. However, the prognostic role of these cells in solid tumors is still not conclusive. Herein, we carried out a meta-analysis including 24 published studies with 6752 patients searched from PubMed, Embase and EBSCO to better comprehend the value of such subpopulation in prognosis prediction for solid tumors. We noted that elevated density of intratumoral PDGFR-β+ fibroblasts was remarkably associated with worse overall survival (OS) and disease-free survival (DFS) of patients. In subgroup analyses, the data showed that PDGFR-β+ fibroblast infiltration considerably decreased OS in non-small cell lung cancer (NSCLC), breast and pancreatic cancer, and reduced DFS in breast cancer. In addition, increased number of PDGFR-β+ fibroblasts appreciably correlated with advanced TNM stage of patients. In conclusion, PDGFR-β+ fibroblast infiltration deteriorates survival in human solid tumors especially in NSCLC, breast and pancreatic cancer. Hence, they may offer a practicable prognostic biomarker and a potential therapeutic strategy for these patients.
- 3 May 2021
- Published by Impact Journals, LLC in Aging
- Vol. 13 (10) , 13693-13707
Open AccessPDGFR-β+ fibroblasts deteriorate survival in human solid tumors: a meta-analysis
Fibroblasts are a highly heterogeneous population in tumor microenvironment. PDGFR-β+ fibroblasts, a subpopulation of activated fibroblasts, have proven to correlate with cancer progression through multiple of mechanisms including inducing angiogenesis and immune evasion. However, the prognostic role of these cells in solid tumors is still not conclusive. Herein, we carried out a meta-analysis including 24 published studies with 6752 patients searched from PubMed, Embase and EBSCO to better comprehend the value of such subpopulation in prognosis prediction for solid tumors. We noted that elevated density of intratumoral PDGFR-β+ fibroblasts was remarkably associated with worse overall survival (OS) and disease-free survival (DFS) of patients. In subgroup analyses, the data showed that PDGFR-β+ fibroblast infiltration considerably decreased OS in non-small cell lung cancer (NSCLC), breast and pancreatic cancer, and reduced DFS in breast cancer. In addition, increased number of PDGFR-β+ fibroblasts appreciably correlated with advanced TNM stage of patients. In conclusion, PDGFR-β+ fibroblast infiltration deteriorates survival in human solid tumors especially in NSCLC, breast and pancreatic cancer. Hence, they may offer a practicable prognostic biomarker and a potential therapeutic strategy for these patients.